A retrospective, cohort study assessing the risk of Guillain-Barré syndrome after administration of recombinant zoster vaccine (RZV or Shingrix)
Latest Information Update: 12 Nov 2021
At a glance
- Drugs GSK 137173A (Primary) ; Varicella zoster virus vaccine live (Primary)
- Indications Herpes zoster; Varicella zoster virus infections
- Focus Adverse reactions
- 11 Nov 2021 New trial record
- 01 Nov 2021 Results published in the JAMA Internal Medicine